Bayer (BAYN) Aktievy
Bayer Aktiengesellschaft är verksamt som ett life science-företag över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för BAYN från våra riskkontroller.
BAYN Community Fair Values
Create NarrativeSee what 258 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€40
FV
8.9% undervärderad intrinsisk rabatt144
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
ST
stuart_roberts
Community ContributorUS$21.53FV • 66.7% undervärderad intrinsisk rabatt
5419.8%Revenue growth p.a.
6.2k
18
0
125
Bayer Aktiengesellschaft Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €36.45 |
| 52 veckors högsta | €49.78 |
| 52 veckors lägsta | €22.02 |
| Beta | 0.89 |
| 1 månads förändring | -6.69% |
| 3 månaders förändring | -17.19% |
| 1 års förändring | 58.27% |
| 3 års förändring | -36.28% |
| 5 års förändring | -31.86% |
| Förändring sedan börsintroduktionen | 167.63% |
Senaste nyheter och uppdateringar
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.
BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.Recent updates
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings
Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside
The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside
Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More
Jan 27
BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside
Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.
BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares
Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential
Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares
Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce
Dec 03BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares
Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 14BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum
Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.Is Bayer (ETR:BAYN) A Risky Investment?
Jul 13
Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health
Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues.Aktieägarnas avkastning
| BAYN | DE Pharmaceuticals | DE Marknad | |
|---|---|---|---|
| 7D | -9.4% | -7.5% | -2.1% |
| 1Y | 58.3% | 9.6% | 1.7% |
Avkastning vs industri: BAYN översteg German Pharmaceuticals branschen som gav 9.6 % under det senaste året.
Avkastning vs Marknaden: BAYN översteg German marknaden som gav 1.7 % under det senaste året.
Prisvolatilitet
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stabil aktiekurs: BAYN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: BAYN s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1863 | 87,280 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft är ett världsomspännande life science-företag. Företaget är verksamt inom segmenten Pharmaceuticals, Consumer Health och Crop Science. Segmentet Pharmaceuticals tillhandahåller receptbelagda produkter främst inom kardiologi och kvinnohälsovård, specialiserade läkemedel inom områdena onkologi, hematologi och oftalmologi, utrustning för bilddiagnostik och kontrastmedel samt cell- och genterapi.
Bayer Aktiengesellschaft Sammanfattning av grunderna
| BAYN grundläggande statistik | |
|---|---|
| Börsvärde | €35.67b |
| Vinst(TTM) | -€3.62b |
| Intäkter(TTM) | €45.58b |
0.8x
P/S-förhållande-9.9x
P/E-förhållandeÄr BAYN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| BAYN resultaträkning (TTM) | |
|---|---|
| Intäkter | €45.58b |
| Kostnad för intäkter | €18.53b |
| Bruttovinst | €27.05b |
| Övriga kostnader | €30.67b |
| Intäkter | -€3.62b |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 12, 2026
| Vinst per aktie (EPS) | -3.68 |
| Bruttomarginal | 59.35% |
| Nettovinstmarginal | -7.94% |
| Skuld/egenkapitalförhållande | 139.3% |
Hur har BAYN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.3%
Aktuell utdelningsavkastning-3%
UtbetalningskvotGer BAYN en tillförlitlig utdelning?
Se BAYN utdelningshistorik och jämförelsetal| Bayer datum för utdelning | |
|---|---|
| Ex utdelningsdag | Apr 27 2026 |
| Utbetalningsdag för utdelning | Apr 29 2026 |
| Dagar till Ex-utdelning | 3 days |
| Dagar till utdelningsdag | 1 day |
Ger BAYN en tillförlitlig utdelning?
Se BAYN utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/29 08:17 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Bayer Aktiengesellschaft bevakas av 40 analytiker. 18 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Emily Field | Barclays |
| Charles Pitman | Barclays |